After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
经过六年的合作,武田退出了微生物组药物协议
- Finch Therapeutics Group Inc (NASDAQ:FNCH) will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Ltd (NYSE:TAK).
- Following a review of its pipeline, Takeda will terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD).
- Also Read: Takeda To Lead Finch-Partnered Microbiome IBD Drug.
- "We are currently conducting a review of our portfolio and assessing the financial and strategic impact of the discontinuation of our collaboration with Takeda," said Mark Smith, CEO of Finch Therapeutics.
- Finch has received more than $44 million from Takeda during the collaboration, including an upfront payment of $10 million, $4 million in milestone payments, and more than $30 million in reimbursement of R&D expenses.
- Upon termination, Finch will receive a royalty-free license to all data and intellectual property generated during the collaboration.
- FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties.
- Price Action: FNCH shares closed at $2.64, and TAK stock closed at $14.02 on Thursday.
- 芬奇治疗集团公司(纳斯达克股票代码:FNCH)将从以下公司重新获得FIN-524(以前称为TAK-524)和FIN-525的全部开发和商业权武田药品株式会社(纽约证券交易所股票代码:Tak)。
- 在对其流水线进行审查后,武田将从2022年11月17日起终止与芬奇的合作,导致芬奇重新获得开发和商业化FIN-524、FIN-525和任何其他用于炎症性肠病(IBD)的微生物组产品的全球权利。
- 另请阅读: 武田将领导与Finch合作的微生物组IBD药物.
- “我们目前正在对我们的投资组合进行审查,并评估我们终止与武田合作的财务和战略影响,”芬奇治疗公司首席执行官马克·史密斯说。
- 芬奇在合作期间从武田收到了超过4400万美元,包括1000万美元的预付款,400万美元的里程碑付款,以及3000多万美元的研发费用报销。
- 终止后,Finch将获得合作期间产生的所有数据和知识产权的免版税许可。
- FIN-524和FIN-525是研究中的、口服给药的靶向微生物组产品,由可能具有免疫调节特性的细菌菌株组成。
- 价格行动:FNCH股价周四收于2.64美元,TAK股价收于14.02美元。